VERAXA Biotech (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company reported that the platform demonstrated selective activity against cancer cells while sparing healthy cells in early testing, and showed dose-dependent destruction of three-dimensional tumor cell spheroids. The announcement comes as VERAXA prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The BiTAC-ADC platform is part of VERAXA's proprietary BiTAC approach, which is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based formats. At the convention, VERAXA is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. The newly released data marks a significant step for the company as it advances its next-generation cancer therapy pipeline. While the platform remains in early development, the results suggest potential for more targeted cancer treatments with fewer side effects.
The company's newsroom provides the latest updates (https://ibn.fm/VRXA). For more details on the full terms of use and disclaimers, visit the InvestorBrandNetwork website (http://IBN.fm/Disclaimer).
